Peter Evan Harwin is Director at Apogee Therapeutics, Inc. (APGE). They have made 5 open-market trades across 4 companies since 2023, most recently 2026-01-22.
CIK 0001663607
4 open-market purchases totalling $30.0M since 2023, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| SYRE | 4,018,101 | $321.2M |
| DNTH | 1,928,503 | $139.2M |
| ZBIO | 2,209,025 | $55.0M |
| APGE | 298,647 | $40.3M |
| CBIO | 2,747,866 | $32.4M |
| Total | $588.2M |
Shares reported on the most recent Form 4, priced at the 2026-01-22 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| APGE | SELL | 2026-01-22 | 2026-01-22 | $76.30 | $133.5M | -11.9% | -10.6% | +16.0% |
| CBIO | BUY | 2025-12-04 | 2025-12-08 | $13.41 | $18.2M | -10.5% | -19.9% | -12.0% |
| ZBIO | BUY | 2025-10-07 | 2025-10-09 | $19.00 | $6.0M | -11.1% | +10.9% | -43.6% |
| ZBIO | BUY | 2024-09-16 | 2024-09-16 | $17.00 | $5.1M | -3.8% | +8.4% | -51.2% |
| DNTH | BUY | 2023-09-29 | 2023-10-03 | $13.63 | $673K | -3.1% | -7.0% | -11.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.